PRA Early Development Clinic
Groningen, Netherlands
NCT Number: NCT02821624
This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data for G1T38 in humans and will allow further development of G1T38 in patients with cancer.
Looking for future studies?
Notify Me40 year–65 year
All sexes
Interventional
Phase 1
Groningen, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CDK 4/6 Inhibitor
Other names: G1T38
Placebo
Time frame: Up to Day 7
All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all subjects receiving study drug through 7 days post dose of study drug.
Time frame: Day 1, 2, 3, 4 and 5
The observed peak plasma concentration determined from the plasma
Time frame: Day 1, 2, 3, 4 and 5
Area under the plasma concentration-time curve
Time frame: Day 1, 2, 3, 4 and 5
G1T38: Plasma- terminal half life (T1/2)
Time frame: Day 1, 2, 3, 4 and 5
Volume of distribution in the terminal elimination phase
G1 Therapeutics, Inc.
Industry
First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details